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Proposed aims, organization, and activities 
of a division of clinical pharmacology 
The general aim of a division of clinical pharmacology is to provide opportunity for the 
work of present clinical pharmacologists, to encourage the development of improved methods 
of research, and, in particular, to foster the training of young men in this discipline. Specific 
areas of research, teaching, and service can already be foreseen. The best administrative 
home of the division will probably be a department of pharmacology, although special 
arrangements regarding budget, personnel, and appOintments will probably be necessary. 
Training in clinical pharmacology should be from 1 to 3 years. The trainee should have 
already received a background of clinical experience, and this may be further strengthened 
during his specific training in clinical pharmacology. Courses in advanced pharmacology and 
statistics are obviously necessary. Each division will probably find it necessary to create at 
least one new course dealing with the special problems of human pharmacology, discussed 
preferably in an informal seminar environment. 
Edward A. Carr, Jr., M.D. Ann Arbor, Mich. 
Departments of lnternal Medicine and Pharmacology (Program in Investigative Clinical 
Pharmacology), University of Michigan 
Approximately twenty medical schools 
in the United States have already estab-
lished or made speCific plans to establish 
divisions, units, or programs in clinical 
pharmacology. Some of these have de-
veloped over a period of a decade or more, 
roughly in parallel with the development 
of individual clinical pharmacologists in 
these schools. Other divisions of clinical 
pharmacology have been recently created, 
under circumstances of somewhat forced 
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development, to meet the rapidly expand-
ing needs. The purpose of the present com-
munication is to suggest that the expe-
rience of the clinical pharmacology groups 
that have developed over the past decade 
is relevant to the further development of 
the field, and should be applied to promote 
reasonably rapid but orderly expansion in 
this area. Since I do not believe that advice 
limited to vague generalities will be of 
much help to those responSible for the de-
velopment of new divisions, an outline of 
specific proposals is presented. 
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I. Background 
At least seven factors have provided the 
impetus for the development of clinical 
pharmacology. 
A. With the explosive increase in the 
number of new compounds for clinical 
testing after World War II, differences be-
tween human reactions to drugs and the 
reactions of other species became increas-
ingly apparent and disturbing. Compara-
tive pharmacology ceased to be a curiosity 
and became, literally, a life-and-death mat-
ter. 
B. This same explosive development led 
to a parallel explosive development of du-
bious therapeutic claims. 
C. A frustrating sense of wasted oppor-
tunities began to affect all those who ob-
served the increasing divergence between 
the basic sciences and clinical medicine. 
Medicine began to develop its own "two 
cultures" problem. 
D. A few techniques of special applica-
bility to man, e.g., the double-blind tech-
nique of drug testing, were developed. 
E. In certain new fields, e.g., the clinical 
use of radioisotopes, the demand for hu-
man use grew quickly. This created the 
need for more background work in experi-
mental pharmacology. In these rapidly ex-
panding areas of human use, clinical 
medicine threatened to outrun its supply 
lines. 
F. A great deal of the work of instruc-
tion in therapeutics fell to the detail men 
of the pharmaceutical industry, by default. 
C. The thalidomide tragedy brought the 
government much more energetically into 
the field. 
II. The present state of the field 
A. No definition of clinical pharmacol-
ogy, satisfactory to everyone, has been de-
veloped. However, the term "clinical phar-
macology" will be used here, as it has taken 
precedence over certain competing terms, 
e.g., human pharmacology, even though 
some of us might prefer other terms. 
B. At various organizational meetings 
devoted to clinical pharmacology, the vari-
Clinical Pharmacology 
and Therapeutics 
ation in background of the individuals at-
tending the meetings has been notable. 
Two features do characterize clinical phar-
macologists: experience in carrying out in-
vestigations in man, and a desire to apply 
the principles of basic sciences, especially 
pharmacology, to such investigations. As 
will be discussed below, these two neces-
sary conditions should not necessarily be 
sufficient conditions to characterize a clin-
ical pharmacologist. 
C. The most notable present trends in 
the programs already developed are the 
availability of fairly large sums of money 
to support training programs, the general 
agreement that any training program 
should include a course in statistics and 
advanced courses in pharmacology, and the 
realization that clinical pharmacologists 
will have to supply many services in con-
nection with the new regulations of the 
Food and Drug Administration. Two other 
trends are disturbing. Certain rump groups 
have moved to set up premature organiza-
tions to act as "certifying boards" in clini-
cal pharmacology. A few individuals may 
have obtained training grants in support 
of clinical pharmacology, and then devoted 
these grants to standard clinical investiga-
tion in a given subspecialty without de-
velopment of a broad clinical pharmacol-
ogy program. These two trends must be 
curbed. 
III. Aims of a division 
of clinical pharmacology 
A. General aims. Regardless of minor 
quarrels in definition, most educated per-
sons would agree that certain activities 
represent "investigations in the basic 
sciences" and certain other activities repre-
sent "the practice of medicine." It is now 
recognized that the transfer of information 
from the first to the second usually involves 
two intermediate stages: a stage of animal 
experimentation conSciously planned as a 
preliminary to investigation in man, and a 
phase of investigation in man before gen-
eral use in practice. Whenever human in-
vestigation goes beyond the making of sim-
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pIe recordings'" from untreated patients 
and involves administration of some sub-
stance to man, speCial problems arise. 
These include problems of ethics, safety, 
evaluation, and required pay-off (i.e., one 
may demand that a study involVing a risk 
to humans have a higher probability of 
yielding valuable information than a study 
carried out in vitro). The crucial charac-
teristic of clinical pharmacology is that it 
differs from pure investigation in the basic 
sciences in that the investigator may have 
a practical (even if far distant) end in 
mind; Simultaneously, the clinical pharma-
cologist differs from the pure practitioner 
of medicine in that the former is trying to 
find out "how things work" in man, while 
the latter is trying to make the most ef-
ficient use of the information that is already 
established. The clinical pharmacolOgist 
differs from certain other clinical investi-
gators in that the former not only recog-
nizes the special problems involved in ad-
ministering substances to humans for ex-
perimental purposes but also wishes to 
e!itablish as many general principles as pos-
sible in this wide field. Moreover, he 
wishes to replicate himself by training oth-
ers in this general field, rather than simply 
training others in the clinical subspecialty 
of his own particular competence. 
Certain distinctions are not germane to 
clinical pharmacology. For example, it does 
not matter whether one is studying a new 
compound or trying to find out more about 
an old one, whether it is to be used for di-
agnostic or for therapeutic purposes, 
whether the substance acts by combining 
with enzymes, emitting beta particles or 
other mechanism, or whether undesirable 
effects are mediated by antibodies, crystals 
in the urine, or other means. 
Perhaps the best analogy is this: be-
tween the "chromosomal" thinking of the 
basic scientist and the "ribosomal" activi-
°The term '·simple recordings" is intended to convey 
the idea that one has not deliberately altered the system 
by administration of a drug. The term is not intended to 
disparage the elegance and importance of much research 
by physiologists. 
ties of the clinician, messenger RNA is 
needed. Clinical pharmacology aspires to 
be the messenger RNA. 
B. Specific aims. A division of clinical 
pharmacology should be active in teach-
ing, research, and service. Only a brief out-
line of the major aims of each is presented 
in this section on aims; further details will 
be found in section V. 
In research, three areas deserve major 
attention: first, the problem of dangerous 
and (at present) unpredictable adverse re-
actions to new drugs in man, such as bone 
marrow depression, anaphylaxis, liver dam-
age, etc.; second, the development of ther-
apeutics as a more rational branch of medi-
cine than it is now; and third, the explOita-
tion of newer areas developed by basic 
scientists. Recent major advances in clin-
ical medicine have continued to explOit, 
for example, basic discoveries made in im-
munology during the last century and prin-
Ciples of chemotherapy developed early 
in this century. This "fossil fuel" of older 
discoveries is being used up rapidly, and 
we must look into newer discoveries of the 
basic scientists for sources for further im-
provement in medicine. 
In teaching, the chief functions should 
be two: to train other investigators in clin-
ical pharmacology, and to prOVide an ap-
proach to more rational therapeutics. 
In service, the chief problem is different 
from that in teaching and research. It will 
be all too easy for clinical pharmacologists 
to find areas in which they can render 
service (see below). But clinical pharma-
cologists must carefully avoid creating arti-
ficial needs for themselves. Thus, a clinical 
pharmacologist must assist investigators 
through a maze of F. D. A. regulations but 
he should be careful not to promote addi-
tional regulations and further bureaucracy, 
simply to create an additional demand for 
his own services. 
IV. Organization of a division 
of clinical pharmacology 
A. Administrative home. Among the 
basic sciences there can be no doubt that 
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pharmacology must be the basis of clinical 
pharmacology. Among clinical departments 
the situation cannot be described so dog-
matically. Throughout this discussion the 
department of internal medicine will be 
used as the reference clinical department, 
as it represents, in many schools, the clini-
cal department most likely to participate 
in clinical pharmacology. But other clinical 
departments, e.g., anesthesiology, may sup-
ply major clinical strength to the division. 
In any event, a logical arrangement would 
place the division of clinical pharmacology 
in the department of pharmacology, with 
the majority of the members of the division 
also holding appointments in clinical de-
partments such as internal medicine. Cer-
tain individuals from other disciplines, e.g., 
physiology, may well hold positions in a 
division of clinical pharmacology. Although 
such other disciplines would not have ma-
jor representation, numerically, in a division 
of clinical pharmacology, those individuals 
from other disciplines who do become 
members of a division of clinical pharma-
cology should receive treatment that is 
scrupulously equal to that given to persons 
connected with the major department of 
the division. In many, probably most, med-
ical schools the best interests of all depart-
ments concerned will be served by such an 
arrangement, which recognizes, realisti-
cally, the importance of the pharmacologic 
basis of clinical pharmacology, the likeli-
hood that several clinical departments may 
form useful associations with it, and the 
fact that activities in the department of in-
ternal medicine are often more applicable 
to clinical pharmacology than to activities 
in certain other clinical departments. 
B. Budget. Although a separate division 
rather than a separate department, clinical 
pharmacology should be supported by its 
own training grant or in some other way 
have its budget allotted separately. This 
will prevent the problem that has been re-
ported to plague other types of scientific 
programs in some schools: Department A 
is already paying large salaries to high-
appointment loafers who spend most of 
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their time in extraneous activities, furnish-
ing little service to the department. This 
means that there is little money available 
for those who are to do the work of the 
department. Meanwhile, Department B al-
ready has a bad tradition of inequality in 
its service demands, and tends to seize 
younger members to do all the work. De-
partment B, therefore, would ordinarily be 
inclined to seize the younger members of 
the clinical pharmacology division and 
make them slave very hard for their wages. 
The best solution is to assign clinical phar-
macology its own tasks and its own funds. 
Then, for example, a clinical pharmacolo-
gist who is appOinted assistant professor in 
internal medicine is not using up funds that 
the professor of medicine should be giving 
to full-time internists; the same applies to 
appointments in the pharmacology depart-
ment. (The matter of service requirements 
is further discussed below.) 
C. Personnel. The director and most of 
the permanent staff of a clinical pharma-
cology division should each meet four cri-
teria. First, they should have had training 
and experience in pharmacology at an ad-
vanced level, beyond that of the usual 
course given to medical students, though 
this does not imply the absolute necessity 
of an advanced degree in pharmacology. 
Second, they should have sufficient clinical 
experience and competence to be accepted 
and trusted by their clinical colleagues in 
some area of clinical medicine, though 
this does not imply the absolute necessity 
of board certification. Third, they should 
have had thorough training in clinical phar-
macology as such. At present, there is only 
one such group, the "first generation" of 
clinical pharmacologists, consisting of in-
dividuals who have had formal training in 
pharmacology and clinical medicine, and 
have also spent several years carrying out 
a program of self-training in clinical phar-
macology. It appears unwise to tum the 
direction of a division of clinical pharma-
cology over to an individual who has not 
had considerable experience and training 
in clinical pharmacology. Therefore, the 
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"first generation" has the duty to organize 
and direct divisions of clinical pharmacol-
ogy. But the "first generation" of clinical 
pharmacologists is obligated to devote 
prompt attention to training a "second gen-
eration," who will in later years assume the 
direction of such divisions. Thus, the fourth 
requirement becomes this: the permanent 
staff of a clinical pharmacology division 
should be willing to devote themselves to 
the teaching and development of this area 
as a field of interest in its own right. 
It is obvious that each division will be 
largely molded by the personal stamp of 
its own staff. This is as it should be in such 
a young field. There is every reason to 
foster such individualism, provided no at-
tempt is made to set the pattern of clinical 
pharmacology in a rigid, premature mold. 
After twenty-five years, the "second gen-
eration" of clinical pharmacologists may 
wish to get together and structure the field 
more rigidly, but this is a matter for future 
decision. 
D. Appointments. The director of a divi-
sion of clinical pharmacology should or-
dinarily hold an appOintment in a clinical 
department ( usually internal medicine) 
equal to that of the head of another divi-
sion, such as hematology, infectious dis-
ease, etc. His appointment in the depart-
ment of pharmacology should be equal to 
that given to the senior members of the 
department next below the chairman. 
Other permanent members of the staff 
should have tenure appointments in phar-
macology and internal medicine (or, in 
speCial instances, other clinical depart-
ments ). Thus, permanent appointment in 
the division of clinical pharmacology would 
usually be a permanent appointment in 
both pharmacology and internal medicine, 
as individuals holding permanent appoint-
ments in a division of clinical pharmacol-
ogy should be genuinely qualified to hold 
such ranks. One exception is foreseen. Un-
der certain circumstances an individual 
with speCial skills, e.g., a statistician, may 
hold a major appointment in clinical phar-
macology without a clinical appointment. 
Since the entire concept of the field is cen-
tered about its bridging function, individ-
uals not qualified in both areas would usu-
ally not hold permanent appointments in 
the division, with the exception of special 
resource persons just mentioned. 
Members of the staff who have not 
reached permanent status should hold an 
appointment such as assistant professor, 
instructor, etc., in one department, either 
pharmacology or internal medicine. If 
qualified to hold a similar appointment in 
the other department, they may do so. 
Otherwise, they may hold an appointment 
such as teaching fellow, research fellow, 
or clinical fellow in the other department. 
Thus, one individual may be an assistant 
professor in pharmacology and assistant 
professor in internal medicine, while an-
other with less clinical experience may be 
an assistant professor in pharmacology and 
clinical fellow in internal medicine. A third 
individual may be an assistant professor in 
internal medicine and research fellow in 
pharmacology. In this way no one would 
be asked to serve in a department in which 
he had no appointment, yet individuals 
would not be given appointments beyond 
their qualifications simply as "prestige" ap-
pointments. 
Ordinarily, the pay and perquisites of 
each member of the division would be 
based upon his highest appointment. 
E. Trainees. Trainees should be in one 
of the following catagories: (1) candidates 
for the permanent staff of the division of 
clinical pharmacology, (2) candidates for 
permanent staff positions in divisions of 
clinical pharmacology elsewhere, or ( 3 ) 
candidates for any regular position in a 
clinical department or pharmacology de-
partment in which the individual, even if 
no longer acting as a full-time clinical 
pharmacologist, can use his special train-
ing in clinical pharmacology to advantage. 
It is also recognized that (4) the practice 
of medicine in the community might well 
be improved if individuals who had speCial 
training in clinical pharmacology would 
enter it. Last, it is expected that (5) some 
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trainees will subsequently find positions in 
governmental or industrial clinical phar-
macology. 
Training in clinical pharmacology should 
be from 1 to 3 years. As present trends in 
medical education already use up many 
precious years of a young man's time, we 
must weigh very carefully each additional 
year we add. It is presumed that the 
trainee in clinical pharmacology will al-
ready have had part of his training in clin-
ical medicine and in pharmacology; there-
fore, he should be able to apply this train-
ing in clinical medicine and in pharmacol-
ogy toward clinical pharmacology, and 
thus avoid the necessity of piling another 
full program of training on one he has al-
ready received. Though a 3 year program 
may be desirable in certain instances, the 
training program in a division of clinical 
pharmacology should more commonly be 
2 years. Upon entry, the trainee should 
have already had an internship, some resi-
dency training or an internship, and some 
advanced pharmacology training. During 
his 2 years of specific training in clinical 
pharmacology, he should attempt to de-
velop at least one clinical skill, take addi-
tional basic pharmacology courses, partici-
pate in a regular seminar in human phar-
macology, take a course in statistics, obtain 
practical experience in teaching therapeu-
tics, carry out a research project in human 
pharmacology together with supporting 
animal work, and obtain practical service 
experience in one or more of the areas 
listed under V, C. 
The 1 year program would ordinarily be 
given to individuals with speCial needs, 
e.g., those described under IV, E. 3 and IV, 
E. 4 (above). Thus, a person with a Ph.D. 
degree in pharmacology, planning a full-
time career in basic pharmacology, may 
elect to take 1 year in clinical pharma-
cology to strengthen his own knowledge of 
human pharmacology; during this year, he 
may well be able to assist in a clinical 
study carried out, for example, by the de-
partment of anesthesiology. As another 
example, a cardiovascular clinical group 
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may be grooming one of its residents for a 
permanent position with them. They may 
wish to have him spend a year of training 
in clinical pharmacology and then supply 
them with this special skill as a member of 
their group. 
F. Space. The division should have its 
offices in close juxtaposition to the depart-
ment of internal medicine or the depart-
ment of pharmacology. It should also have 
laboratories for supporting animal work, 
and space for clinical investigation. Thus, 
the division should have laboratory space 
in connection with internal medicine, labor-
atory space in connection with pharma-
cology, and offices adjacent to one of these 
sets of laboratories. The necessity for travel 
from one area to another may impose loss 
of time on the members of the division but 
this is a necessary price to pay. Ambassa-
dors who object to travel have chosen the 
wrong career! 
V. Functions of the division 
(please note III, B, 1) 
A. Teaching. 
1. The division should organize the 
training of clinical pharmacologists. It 
should be directly responsible for conduct-
ing a regular seminar in human pharma-
cology. 
2. The division should be in charge of 
teaching rational therapeutics based upon 
pharmacology to third and fourth year 
medical students, to the house staff, and to 
postgraduate groups. (See also V, C, 1, 
next page.) 
3. Whenever pOSSible, each member of 
the division should also give certain lec-
tures in the basic second year pharma-
cology course, if for no other reason than 
for the good of his own soul. 
4. Divisions of pharmacology should 
probably avoid heavy participation in 
mammoth undertakings to integrate all the 
basic sciences and all the clinical specialties 
into one huge correlation program. Inte-
gration among several basic sciences has 
proved successful in some schools, and inte-
gration among several clinical specialties 
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may be desirable and pOSSible. But the dif-
ficulties of integration between basic sci-
ence and clinical medicine are now such 
that clinical pharmacology, in attempting 
to solve this problem, should at present 
limit its objectives to the areas discussed 
above. 
B. Research. 
1. Members of the division, particularly 
in the early part of their careers, may carry 
out any bona fide research project in basic 
science to master principles and techniques. 
2. Similarly, clinical pharmacology of 
the routine therapeutic trial type may also 
be carried out as a necessary research 
function of the department. 
3. However, the principal research de-
sired is the careful observation of the ef-
fect of drugs in selected patients in order 
to learn more about human pharmacology, 
and the imaginative development of animal 
or other basic techniques to improve the 
predictability of undesirable reactions in 
man. 
4. On many occasions it may be desir-
able for a member of the division to do 
detached service with a well-established 
clinical investigator. There is no objection 
to this, prOVided, however, the detach-
ment is not too complete. Thus, a labora-
tory meeting of the division should be held 
once a week and all members carrying out 
research in the division should take part. 
At this time, each trainee will learn about 
the problems of clinical pharmacology in 
clinical areas other than the one in which 
he is interested, and will also submit his 
own work to the criticism of his colleagues. 
Experience suggests that members of a 
division must avoid being seduced by the 
advantages of animal work to the point 
that they abandon the more difficult in-
vestigations in man. 
5. The conduct of routine, unimaginative 
drug testing has not been mentioned in the 
description of research activities thus far. 
This omission is anything but accidental. 
Any division of clinical pharmacology that 
allows itself to be converted into a mill 
grinding out a stream of drug tests will 
certainly have no time to contribute to a 
solution of the many fascinating problems 
that should concern the true clinical 
pharmacologist, i.e., the absorption, distri-
bution, elimination, special toxicity, usual 
and unusual effects, etc., of drugs in man. 
Therefore, the degeneration of clinical 
pharmacology into simple drug testing 
would be a development as unfortunate as 
it is unnecessary. 
C. Services. 
1. Each individual in the division, inso-
far as his clinical competence permits, 
should render clinical service such as ward 
rounds, outpatient service, etc. 
2. The development of a speCial therapy 
clinic to carry out certain projects in ex-
perimental therapeutiCS should be consid-
ered. The specific type of work to be car-
ried out in the speCial therapy clinic may 
vary from year to year, and the details of 
admission of a patient to the special ther-
apy clinic require careful consideration 
from the ethical, clinical, financial, and 
legal standpoints. The experience of clinical 
research units to date suggests that such 
special arrangements are indeed feasible 
and successful. 
3. The clinical pharmacologist must be 
fully cognizant of the details and implica-
tions of F. D. A. regulations, the practical 
methods of meeting requirements of the 
law, etc. He must give practical aid to 
other investigators and to the school itself 
in these matters. 
4. Clinical pharmacologists should be 
available to give advice in the conduct of 
research in man to any other group that 
asks for such advice, within the school. 
5. Clinical pharmacologists should play 
a major role in the organization and func-
tion of the poison control center of the 
medical school's hospital. 
6. Clinical pharmacologists should be 
available for clinical consultation in mat-
ters of undesirable reactions to drugs, etc. 
They should organize and direct a program 
for collection and reporting of adverse 
reactions to drugs within a medical cen-
ter. 
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7. The Pharmacy and Therapy ( or 
Formulary) Committee should have the 
services of a clinical pharmacologist. 
8. Each school, to make best use of a 
division of clinical pharmacology, should 
also consider its own peculiar characteris-
tics as a medical school, and determine the 
ways in which a division of clinical pharma-
cology can best be fitted to these peculiar 
characteristics by carrying out additional 
special duties. 
9. A serious warning should be men-
tioned here. Unless the duties of each 
member of the division are carefully spelled 
out, he is likely to be either hopelessly 
overworked or underutilized. The principle 
of "1fa-1fa-1h" should be considered here. 
Ordinarily, a clinical pharmacologist hold-
ing an appointment in pharmacology and 
in a clinical department would owe the 
clinical department one third the amount 
of service time (outpatient service, etc.) 
that the regular members of that depart-
ment (of similar rank) devote to such serv-
ice. He would owe the pharmacology de-
partment one third the amount of service 
time (student laboratory, etc.) that the 
regular full-time members of the depart-
ment (of similar rank) devote to such 
service. The remaining one third of his 
service time would be devoted to his 
speCial services as a clinical pharmacolo-
gist, as described above. Experience has 
shown that departments with a strong, 
just organization, in which each full-time 
member of the department really does 
carry out his fair share of service, fit well 
into such a plan, for it is then possible to 
make a realistic fractionation. Thus, if each 
associate professor in the department of 
internal medicine ordinarily gives X hours 
of service, and each associate professor in 
the department of pharmacology gives Y 
hours of service, then an associate profes-
sor of pharmacology and internal medicine 
in the clinical pharmacology division would 
give one third X plus one third Y plus Z 
hours of service. Z would represent service 
on the poison control center, assistance in 
teaching the human pharmacology seminar, 
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speCial consultations in clinical pharma-
cology on the wards, etc. If the individual's 
talents and inclinations made it more rea-
sonable for him to give two thirds X 
hours and no Y hours (or the reverse) this 
might be acceptable under certain circum-
stances. 
VI. Additional considerations 
A. A major problem of the division of 
clinical pharmacology will lie in recruiting. 
Most of the young men now entering 
training have come to see success in the 
basic sciences as lying in the study of 
molecules and smaller particles. Success 
in clinical medicine is seen to lie in certifi-
cation by the boards and training in an 
established subspecialty. Thus, a clinical 
pharmacology division should not expect 
to have a large number of trainees at the 
outset. It may, however, take advantage 
of the flexibility available to a new field. 
Examples of individuals who may profit 
from 1 year of training in the field as well 
as those who may profit from 2 and 3 years 
of training in the field have been presented. 
Examples of the various careers subse-
quently open to persons trained in clinical 
pharmacology have also been presented. 
These should be advertised judiciously but 
not blatantly. 
B. It is to be hoped that divisions of 
clinical pharmacology will be able to re-
verse a trend that is now developing in 
certain medical schools. Pharmacologists 
as such are giving way to pure biochemists, 
etc. This is not to disparage the vitally im-
portant role of pure biochemists, etc., in 
medical schools but the waning influence 
of classical pharmacology is not a healthy 
development. Meanwhile, clinicians see an 
increasing need for medical students to 
receive proper background in pharma-
cology in preparation for the modem 
practice of medicine. In certain European 
countries, pharmacology has long been as-
sociated with the clinical years, and it 
would not be inconceivable for clinical 
groups to decide their students would re-
quire a new course in fundamentals of 
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therapeutics, to be given in the clinical 
years, as a replacement for orthodox phar-
macology, if pharmacology should become 
increasingly separated from clinical medi-
cine. Such a development would probably 
not be a healthy one. Therefore, a division 
of clinical pharmacology may go far to stop 
the divorce proceedings which at present 
seem to be pending between two major 
areas in medicine. 
